Dr. George on Sequencing in Renal Cell Carcinoma

Daniel J. George, MD
Published: Tuesday, Dec 18, 2018



Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

There are many factors to consider when selecting and sequencing therapy, one of which is risk status. Good-risk patients tend to have a manageable tumor burden and live a long time, says George. However, many good-risk, low-volume patients can get by with active surveillance. Intermediate risk comprises the largest risk category of RCC patients at about 60%, explains George. Physicians should take a proactive approach for these patients, as they can be unpredictable. Typically, an immunotherapy-based regimen is a suitable treatment option.

Treatment for patients with poor-risk disease depends on tolerability, states George. Many patients may require palliation, and drugs such as cabozantinib (Cabometyx) can result in very quick responses, which can be helpful. Some patients may have an overwhelming burden of disease, in which case palliation and supportive care take precedence.
SELECTED
LANGUAGE


Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

There are many factors to consider when selecting and sequencing therapy, one of which is risk status. Good-risk patients tend to have a manageable tumor burden and live a long time, says George. However, many good-risk, low-volume patients can get by with active surveillance. Intermediate risk comprises the largest risk category of RCC patients at about 60%, explains George. Physicians should take a proactive approach for these patients, as they can be unpredictable. Typically, an immunotherapy-based regimen is a suitable treatment option.

Treatment for patients with poor-risk disease depends on tolerability, states George. Many patients may require palliation, and drugs such as cabozantinib (Cabometyx) can result in very quick responses, which can be helpful. Some patients may have an overwhelming burden of disease, in which case palliation and supportive care take precedence.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x